0K9E Stock Chart & Stats
$155.23
$3.31(2.12%)
At close: 4:00 PM EDT
$155.23
$3.31(2.12%)
Day’s Range― - ―
52-Week Range$114.51 - $170.29
Previous CloseN/A
Volume62.00
Average Volume (3M)30.18K
Market Cap
$286.53B
Enterprise Value$341.69K
Total Cash (Recent Filing)$7.69B
Total Debt (Recent Filing)$49.01B
Price to Earnings (P/E)23.8
Beta0.88
Next Earnings
Oct 27, 2026EPS Estimate
2.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.66
Shares Outstanding2,034,819,500
10 Day Avg. Volume626
30 Day Avg. Volume30,176
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)5.79
Price to Sales (P/S)4.88
P/FCF Ratio15.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$159.00Price Target Upside2.43% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)8.78
Revenue Forecast (FY)$57.02B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIncreased cash on the balance sheet has led to a modestly higher target price for Novartis.
Product ApprovalCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.
Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Bears Say
Revenue ExpectationsThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
Novartis News
0K9E FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest share price was $114.51 and its highest was $170.29 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is $286.53B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Oct 27, 2026 which is in 81 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Jul 21, 2026. The company reported $2.41 earnings per share for the quarter, beating the consensus estimate of $2.172 by $0.238.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Undervalued.
Does Novartis Ag pay dividends?
Novartis Ag does not currently pay dividends.
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 2.22.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,034,819,500 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $2.41 in its last earnings report, beating expectations of $2.172. Following the earnings report the stock price went up 1.713%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in GB:0K9E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novartis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$159.00 (2.43% Upside)
$159.00 (2.43% Upside)
Blogger Sentiment
Bullish
GB:0K9E Sentiment 62%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.55%
12-Months-Change
Fundamentals
Return on Equity
3.02%
Trailing 12-Months
Asset Growth
16.90%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
0K9E Company Deck
0K9E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and pipeline picture: multiple priority brands delivered high double-digit growth, Q2 returned to net sales growth, important regulatory and biomarker milestones were achieved, and management reaffirmed full-year guidance while outlining a busy H2 of pivotal readouts. Offsetting risks include H1 generic erosion and margin pressure (partly acquisition-related), temporary phasing effects that favor Q2, and several high-impact clinical readouts and regional competitive pressures that remain uncertain. On balance, the upside from strong product momentum, cash generation and pipeline progress outweighs the near-term headwinds.View all GB:0K9E earnings summaries0K9E Stock 12 Month Forecast
Average Price Target
$159.00
▲(2.43% Upside)